Tamsulosin: Current clinical experience

Urology

Volumn 58, Issue 6 SUPPL. 1, 2001, Pages 42-48

  O'Leary, Michael P ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Division of Urology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; PLACEBO; RECEPTOR SUBTYPE; TAMSULOSIN; TERAZOSIN;

AGING; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION; HEADACHE; HUMAN; HYPERTENSION; MALE; MALE SEXUAL DYSFUNCTION; ORTHOSTATIC HYPOTENSION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SYMPTOM; TIME; URETHRA; URINARY TRACT OBSTRUCTION; URINE FLOW RATE; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; EJACULATION; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC, ALPHA-1; SULFONAMIDES;

EID: 0035665753     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01346-2     Document Type: Conference Paper

References (18)

1. The development of human benign prostatic hyperplasia with age
2. Finasteride; a review of its potential in the treatment of benign prostatic hyperplasia
3. Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia
4. Alpha blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it
5. Future concepts in the medical therapy of benign prostatic hyperplasia
6. Benign prostatic hyperplasia; practical treatment guidelines
7. 1C subtype
8. 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy
9. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia
10. Long-term evaluation of tamsulosin in benign prostatic hyperplasia; placebo-controlled, double-blind extension of phase III trial
11. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia
12. Clinical evaluation of tamsulosin, a prostate selective alpha1C antagonist
13. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia; pharmacodynamic effect
14. Tamsulosin 0; 4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
15. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia
16. Michel MC, Newmann HG, Mehlburger L, et al.: Does the time of administration (morning or evening) affect the tolerability or efficacy of tamsulosin